In 127 infants admitted to intensive care for RSV bronchiolitis, concomitant bacterial sepsis was a rare event. However, in the subgroup of intubated patients the incidence of bacterial pneumonia was 43.9% (95% CI 31.0-56.8%), half community acquired and half nosocomial. As clinical signs are not helpful in identifying these patients, tracheal aspirates have to be investigated microbiologically on a routine basis in order to start antibiotics in time.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1719766 | PMC |
| http://dx.doi.org/10.1136/adc.2004.049551 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study.
Eur J Pediatr
March 2025
SAMU 93 - SMUR - Emergency Department, Avicenne Hospital, Public Assistance Hospitals Paris, Bobigny, France.
Unlabelled: Respiratory syncytial virus (RSV) is a leading cause of infant morbidity. France has implemented a national campaign using nirsevimab to prevent RSV-related infections in infants. This study assessed its effectiveness in preventing hospitalization due to bronchiolitis in emergency department (ED).
View Article and Find Full Text PDFRespiratory Syncytial Virus Burden in Premature Infants: The Role of Season With and Without RSV Immunoprophylaxis in a Multicenter Study.
Pediatr Pulmonol
March 2025
Pediatric Pulmonology Unit, Wolfson Medical Center, Holon, Israel.
Objective: To compare the Respiratory Syncytial Virus (RSV) hospitalization burden among 29-34 weeks gestational age (wGA) preterm infants between seasons with and without routine palivizumab prophylaxis, by utilizing the 2021 off-season RSV surge.
Methods: This multi-center retrospective study was conducted in 11 medical centers across Israel. We included infants > 1 year-old, with wGA data, hospitalized with RSV infection from November 2017-August 2021.
Call to include breastfeeding as a synergistic approach to vaccines for prevention of respiratory syncytial virus disease.
Int Breastfeed J
March 2025
Chair of Public Health and Health Services Research, Institute for Biostatistics, Epidemiology, Medical Information Processing, Medical Faculty, Ludwig-Maximilians-Universität München (LMU Munich), Munich, Germany.
Background: Infections with respiratory syncytial virus (RSV) in infancy and early childhood are very common. RSV is the leading cause of bronchiolitis and pneumonia and substantially contributes to the morbidity and mortality of infants and young children worldwide. Until very recently, there have been no vaccines available for prevention and there are no curative treatments for RSV.
View Article and Find Full Text PDFRecommendation for immune prophylaxis of respiratory syncytial virus infection in children.
J Microbiol Immunol Infect
February 2025
Division of Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taiwan.
Respiratory syncytial virus (RSV) is the most common pathogen for young children hospitalized with bronchiolitis and pneumonia. Most infections occur below 1 year of age, and almost all children have been infected before 2 years of age. Monoclonal antibodies targeting RSV, such as palivizumab and nirsevimab, are accessible for preventing infection.
View Article and Find Full Text PDFRespiratory syncytial virus immunization with nirsevimab: Acceptance and satisfaction assessment in infants and risk groups in the region of Murcia (Spain).
Hum Vaccin Immunother
December 2025
Prevention and Health Protection Service, Public Health and Addictions Directorate General, Regional Ministry of Health, Murcia, Spain.
Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants under two years of age, often resulting in bronchiolitis and pneumonia, which contribute to high hospitalization rates. The recent approval of nirsevimab, a long-acting monoclonal antibody, has provided an immunization alternative for infants, addressing the substantial burden of RSV. This study aimed to evaluate acceptance and satisfaction among parents or legal guardians of infants who were candidates for immunization with nirsevimab in the Region of Murcia (Spain) during the 2023-2024 campaign.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!